Literature DB >> 28009083

Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis.

Anne-Katrin Güttsches1, Stefen Brady2, Kathryn Krause1,3, Alexandra Maerkens1,3, Julian Uszkoreit3, Martin Eisenacher3, Anja Schreiner1, Sara Galozzi3, Janine Mertens-Rill1, Martin Tegenthoff1, Janice L Holton4,5, Matthew B Harms6, Thomas E Lloyd7, Matthias Vorgerd1, Conrad C Weihl8, Katrin Marcus3, Rudolf A Kley1.   

Abstract

OBJECTIVE: Sporadic inclusion body myositis (sIBM) pathogenesis is unknown; however, rimmed vacuoles (RVs) are a constant feature. We propose to identify proteins that accumulate within RVs.
METHODS: RVs and intact myofibers were laser microdissected from skeletal muscle of 18 sIBM patients and analyzed by a sensitive mass spectrometry approach using label-free spectral count-based relative protein quantification. Whole exome sequencing was performed on 62 sIBM patients. Immunofluorescence was performed on patient and mouse skeletal muscle.
RESULTS: A total of 213 proteins were enriched by >1.5 -fold in RVs compared to controls and included proteins previously reported to accumulate in sIBM tissue or when mutated cause myopathies with RVs. Proteins associated with protein folding and autophagy were the largest group represented. One autophagic adaptor protein not previously identified in sIBM was FYCO1. Rare missense coding FYCO1 variants were present in 11.3% of sIBM patients compared with 2.6% of controls (p = 0.003). FYCO1 colocalized at RVs with autophagic proteins such as MAP1LC3 and SQSTM1 in sIBM and other RV myopathies. One FYCO1 variant protein had reduced colocalization with MAP1LC3 when expressed in mouse muscle.
INTERPRETATION: This study used an unbiased proteomic approach to identify RV proteins in sIBM that included a novel protein involved in sIBM pathogenesis. FYCO1 accumulates at RVs, and rare missense variants in FYCO1 are overrepresented in sIBM patients. These FYCO1 variants may impair autophagic function, leading to RV formation in sIBM patient muscle. FYCO1 functionally connects autophagic and endocytic pathways, supporting the hypothesis that impaired endolysosomal degradation underlies the pathogenesis of sIBM. Ann Neurol 2017;81:227-239.
© 2017 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28009083      PMCID: PMC5323275          DOI: 10.1002/ana.24847

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  53 in total

Review 1.  Molecular pathology and pathogenesis of inclusion-body myositis.

Authors:  Valerie Askanas; W King Engel
Journal:  Microsc Res Tech       Date:  2005-07       Impact factor: 2.769

2.  ATOH8: a novel marker in human muscle fiber regeneration.

Authors:  Anne-K Güttsches; Ajeesh Balakrishnan-Renuka; Rudolf André Kley; Martin Tegenthoff; Beate Brand-Saberi; Matthias Vorgerd
Journal:  Histochem Cell Biol       Date:  2014-12-17       Impact factor: 4.304

3.  A direct regulatory interaction between chaperonin TRiC and stress-responsive transcription factor HSF1.

Authors:  Daniel W Neef; Alex M Jaeger; Rocio Gomez-Pastor; Felix Willmund; Judith Frydman; Dennis J Thiele
Journal:  Cell Rep       Date:  2014-10-30       Impact factor: 9.423

4.  Expression of the intermediate filament protein synemin in myofibrillar myopathies and other muscle diseases.

Authors:  Montse Olivé; Lev Goldfarb; Ayush Dagvadorj; Nyamkhishig Sambuughin; Denise Paulin; Zhenlin Li; Bertrand Goudeau; Patrick Vicart; Isidro Ferrer
Journal:  Acta Neuropathol       Date:  2003-04-01       Impact factor: 17.088

5.  Autophagy-mediated clearance of aggresomes is not a universal phenomenon.

Authors:  Esther S P Wong; Jeanne M M Tan; Wen-E Soong; Kamila Hussein; Nobuyuki Nukina; Valina L Dawson; Ted M Dawson; Ana Maria Cuervo; Kah-Leong Lim
Journal:  Hum Mol Genet       Date:  2008-05-23       Impact factor: 6.150

6.  p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy.

Authors:  Serhiy Pankiv; Terje Høyvarde Clausen; Trond Lamark; Andreas Brech; Jack-Ansgar Bruun; Heidi Outzen; Aud Øvervatn; Geir Bjørkøy; Terje Johansen
Journal:  J Biol Chem       Date:  2007-06-19       Impact factor: 5.157

7.  Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle.

Authors:  Gaetano Vattemi; W King Engel; Janis McFerrin; Valerie Askanas
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

8.  Proteomic study of sporadic inclusion body myositis.

Authors:  Ke Li; Chuanqiang Pu; Xusheng Huang; Jiexiao Liu; Yanling Mao; Xianghui Lu
Journal:  Proteome Sci       Date:  2014-09-12       Impact factor: 2.480

9.  Defining the TRiC/CCT interactome links chaperonin function to stabilization of newly made proteins with complex topologies.

Authors:  Alice Y Yam; Yu Xia; Hen-Tzu Jill Lin; Alma Burlingame; Mark Gerstein; Judith Frydman
Journal:  Nat Struct Mol Biol       Date:  2008-11-16       Impact factor: 15.369

10.  A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis.

Authors:  Stefen Brady; Waney Squier; Caroline Sewry; Michael Hanna; David Hilton-Jones; Janice L Holton
Journal:  BMJ Open       Date:  2014-04-28       Impact factor: 2.692

View more
  21 in total

Review 1.  Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Authors:  Elie Naddaf; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

2.  234th ENMC International Workshop: Chaperone dysfunction in muscle disease Naarden, The Netherlands, 8-10 December 2017.

Authors:  Conrad C Weihl; Bjarne Udd; Michael Hanna
Journal:  Neuromuscul Disord       Date:  2018-09-25       Impact factor: 4.296

Review 3.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

Review 4.  New Developments in the Genetics of Inclusion Body Myositis.

Authors:  Kyla A Britson; Stephanie Y Yang; Thomas E Lloyd
Journal:  Curr Rheumatol Rep       Date:  2018-04-02       Impact factor: 4.592

5.  FYCO1 regulates accumulation of post-mitotic midbodies by mediating LC3-dependent midbody degradation.

Authors:  Lai Kuan Dionne; Eric Peterman; John Schiel; Paulius Gibieža; Vytenis Arvydas Skeberdis; Antonio Jimeno; Xiao-Jing Wang; Rytis Prekeris
Journal:  J Cell Sci       Date:  2017-12-01       Impact factor: 5.285

Review 6.  Histopathology of Duchenne muscular dystrophy in correlation with changes in proteomic biomarkers.

Authors:  Margit Zweyer; Hemmen Sabir; Paul Dowling; Stephen Gargan; Sandra Murphy; Dieter Swandulla; Kay Ohlendieck
Journal:  Histol Histopathol       Date:  2021-12-07       Impact factor: 2.303

Review 7.  Genetics in inclusion body myositis.

Authors:  Simon Rothwell; James B Lilleker; Janine A Lamb
Journal:  Curr Opin Rheumatol       Date:  2017-11       Impact factor: 5.006

Review 8.  Immune and myodegenerative pathomechanisms in inclusion body myositis.

Authors:  Christian W Keller; Jens Schmidt; Jan D Lünemann
Journal:  Ann Clin Transl Neurol       Date:  2017-05-16       Impact factor: 4.511

9.  Proteomic Profiling Unravels a Key Role of Specific Macrophage Subtypes in Sporadic Inclusion Body Myositis.

Authors:  Andreas Roos; Corinna Preusse; Denisa Hathazi; Hans-Hilmar Goebel; Werner Stenzel
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

Review 10.  Current Classification and Management of Inflammatory Myopathies.

Authors:  Jens Schmidt
Journal:  J Neuromuscul Dis       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.